Key result
This in-depth review highlights the ongoing evolution in diagnostic criteria, risk stratification, and management of Brugada syndrome based on current clinical guidelines and literature.
Why the study?
Ongoing evolution, reclassification, and rethinking of Brugada syndrome diagnostic criteria, risk stratification, and management are occurring as basic science, registry, and clinical trial data shape understanding.
This review provides an updated perspective on the diagnosis, risk stratification, and management of Brugada syndrome based on current literature and guidelines.
Supports evolving Brugada syndrome care; leaves open prospective validation of updated risk models.
Since the first reported descriptions of Brugada syndrome, there has been a growing awareness and appreciation of the disease and its implications. From the diagnostic criteria, to risk stratification and management, there is an ongoing evolution, reclassification and re-thinking of Brugada syndrome as basic science, registry and clinical trial data shape our understanding of the pathophysiology and its clinical implications. This in-depth review sheds light on the most important literature to date, highlighting insights that shifted the global perspective on the disease. Current clinical paradigms and guidelines are presented, along with their justification, and possible opportunities for future research are explored.
No takes yet. Share an insight, caveat, or question.
Walia et al. (2019) conducted a review in Brugada syndrome. This in-depth review highlights the ongoing evolution in diagnostic criteria, risk stratification, and management of Brugada syndrome based on current clinical guidelines and literature.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: